1. Generics Bulletin
  2. >>Legal & IP

Apotex Is Latest To Accuse Amarin Of ‘Freezing Out’ Vascepa Competition

Becomes Fourth Antitrust Suit Alleging Amarin Has ‘Deviated From Industry Practice’

 
• By Dean Rudge

Apotex is the latest generics manufacturer that feels Amarin has engineered a “systematic effort to ensure that no other company could manufacture the generic version of its product,” Vascepa, by locking up API supply, with the Canadian firm taking legal action in a bid to bring the originator’s alleged conduct to a halt.

• Source: Alamy

First Dr Reddy’s, then Hikma, then Teva, now Apotex. The Canadian firm is the latest generics manufacturer to file an antitrust lawsuit against Amarin, accusing the originator of an anticompetitive scheme to “delay, hinder, and frustrate robust generic competition” to its Vascepa (icosapent ethyl) purified fish oil brand by “locking up” the supply of the brand’s active pharmaceutical ingredient.

“For Amarin, it is Vascepa or bust. The company has no other products and no meaningful pipeline behind Vascepa,” Apotex...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

Henlius And Organon Sued In US Over Plans To Market Perjeta Biosimilar

 
• By Dean Rudge

Roche and its Genentech subsidiary have sued Shanghai Henlius Biotech and commercialization partner Organon in the US, alleging infringement of 24 patents covering Perjeta (pertuzumab). The litigation follows Roche’s recent disclosure that biosimilars to Perjeta could launch as soon as 2026.

UPC Imposes Wide Cross-Border Injunction On Zentiva In Ofev Patent Clash

 
• By Dean Rudge

The UPC Court of Appeal has signaled that in pharma disputes, being ready to launch can be as risky as actually launching. In a major setback for Zentiva, the court ruled that completing certain steps well before patent expiry amounted to “setting the stage” for infringement.

UK Decision Opens Up Competition On Forxiga

 
• By Dave Wallace

Generic dapagliflozin rivals to AstraZeneca’s Forxiga are now free to hit the UK market after the country’s Supreme Court lifted the final barrier preventing launch, allowing off-patent firms access to a market worth hundreds of millions of pounds annually.

Sandoz Rushes To Fill Gap After German Court Revokes Xarelto Patent

 
• By Dean Rudge

Germany’s Federal Patent Court has invalidated Bayer’s key patent covering once-daily use of Xarelto (rivaroxaban), paving the way for Sandoz to launch a generic version. Bayer is considering an appeal.

More from Generics Bulletin

Alvotech Focuses On Value Over Volume As Sales Continue To Grow

 
• By Dave Wallace

As Alvotech announced first-half results that outpaced expectations, the biosimilars developer’s management explained that the firm was targeting value and product margin over market share and volumes.

Generic Drug Industry Seeks More US FDA Communication Reforms In GDUFA Renewal

 
• By Sue Sutter

Enhancing the consistency and clarity of information requests and discipline review letters, and improving assessment milestone communications are key areas targeted by generic drug makers for user fee program negotiations.

Danish Probe Could Influence Rethink Of Controversial EU Urban Wastewater Rules

 
• By Francesca Bruce

Some medicines may be subject to price rises that make them unaffordable if the burden of paying for extra wastewater treatment is not more fairly distributed across different industries, the Danish pharmaceutical industry association has warned.